Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Issue 13 (10th November 2022) - Ball, Brian J.; Arslan, Shukaib; Koller, Paul; Ngo, Dat; Afkhami, Michelle; Salhotra, Amandeep; Al-Malki, Monzr; Aribi, Ahmed; Ali, Haris; Sandhu, Karamjeet; Otoukesh, Salman; Amanam, Idoroenyi; et al.